Strategies to improve radiotherapy with targeted drugs, Nat Rev Cancer, vol.11, pp.239-53, 2011. ,
The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines, Cancer, vol.104, pp.1129-1166, 2005. ,
Radioimmunotherapy for B-cell non-hodgkin lymphomas, Cancer Control, vol.19, pp.196-203, 2012. ,
Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer, Cancer, vol.116, pp.1118-1143, 2010. ,
The new golden era for radioimmunotherapy: not just for lymphomas anymore, Cancer Control, vol.20, pp.60-71, 2013. ,
Hallmarks of cancer: the next generation, Cell, vol.144, pp.646-74, 2011. ,
Immune suppressive mechanisms in the tumor microenvironment, Current Opinion in Immunology, vol.39, pp.1-6, 2016. ,
Whole Body Irradiation-Radiobiology or Medicine?, Br J Radiol, vol.26, pp.234-275, 1953. ,
Radiation-induced bystander effects--implications for cancer, Nat Rev Cancer, vol.4, pp.158-64, 2004. ,
Radiation-induced bystander signalling in cancer therapy, Nat Rev Cancer, vol.9, pp.351-60, 2009. ,
Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy, Oncoimmunology, vol.1, pp.407-415, 2012. ,
Abscopal regression in lymphoma: a mechanism in common with total body irradiation?, Clin Radiol, vol.32, pp.475-80, 1981. ,
Lymphangiographic demonstration of the abscopal effect in patients with malignant lymphomas, Int. J. Radiat. Oncol. Biol. Phys, vol.2, pp.141-148, 1977. ,
The abscopal effect and chronic lymphocytic leukemia, Am. J. Med, vol.98, pp.307-315, 1995. ,
The beneficial local and abscopal effect of splenic irradiation in frail patients with chronic lymphocytic leukaemia, Neth J Med, vol.74, pp.122-131, 2016. ,
The abscopal effect associated with a systemic anti-melanoma immune response, Int. J. Radiat. Oncol. Biol. Phys, vol.85, pp.293-298, 2013. ,
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy, Oncoimmunology, vol.3, p.28780, 2014. ,
Abscopal effect in a patient with metastatic Merkel cell carcinoma following radiation therapy: potential role of induced antitumor immunity, Arch Dermatol, vol.147, pp.870-872, 2011. ,
Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis, Gut, vol.43, pp.575-582, 1998. ,
Spontaneous regression of thoracic metastases while progression of brain metastases after stereotactic radiosurgery and stereotactic body radiotherapy for metastatic renal cell carcinoma: abscopal effect prevented by the blood-brain barrier?, Clin Genitourin Cancer, vol.10, pp.196-204, 2012. ,
Abscopal effect of radiation on toruliform para-aortic lymph node metastases of advanced uterine cervical carcinoma--a case report, Anticancer Res, vol.27, pp.499-503, 2007. ,
Manipulating dendritic cell biology for the active immunotherapy of cancer, Blood, vol.104, pp.2235-2281, 2004. ,
Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer, Cancer Research, vol.59, pp.6028-6060, 1999. ,
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated, Int. J. Radiat. Oncol. Biol. Phys, vol.58, pp.862-70, 2004. ,
Enhancement of antitumor radiation efficacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of macrophage inflammatory protein-1alpha, Clin. Cancer Res, vol.14, pp.1159-66, 2008. ,
Systemic effects of local radiotherapy, Lancet Oncol, vol.10, pp.718-744, 2009. ,
Is tumor (R)ejection by the immune system the "5th R" of radiobiology?, Oncoimmunology, vol.3, p.28133, 2014. ,
Modulation of inflammation by low and high doses of ionizing radiation: Implications for benign and malign diseases, Cancer Lett, vol.368, pp.230-237, 2015. ,
The impact of radiation therapy on the antitumor immunity: local effects and systemic consequences, Cancer Lett, vol.356, pp.114-139, 2015. ,
Radiation triggering immune response and inflammation, Cancer Lett, vol.368, pp.156-63, 2015. ,
Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways, PLoS ONE, vol.7, p.31762, 2012. ,
Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation, Exp. Mol. Med, vol.38, pp.474-84, 2006. ,
Modulation of death receptor-mediated apoptosis in differentiating human myeloid leukemia HL-60 cells, J. Leukoc. Biol, vol.69, pp.794-802, 2001. ,
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy, J. Immunol, vol.170, pp.6338-6385, 2003. ,
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes, Cancer Research, vol.64, pp.7985-94, 2004. ,
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy, J. Exp. Med, vol.203, pp.1259-71, 2006. ,
gamma-ray irradiation induces B7.1 expression in myeloid leukaemic cells, Br. J. Haematol, vol.108, pp.825-856, 2000. ,
The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing, Clin. Cancer Res, vol.14, pp.4241-4250, 2008. ,
Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects, Cancer Immunol Immunother, vol.57, pp.1173-83, 2008. ,
Enhancement of B7-1 (CD80) expression on B-lymphoma cells by irradiation, Immunology, vol.96, pp.642-650, 1999. ,
Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells, Int. J. Cancer, vol.93, pp.539-587, 2001. ,
Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization, Cancer Research, vol.61, pp.8105-8114, 2001. ,
Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1, Proc. Natl. Acad. Sci. U.S.A, vol.104, pp.8444-8452, 2007. ,
Chemotherapy and radiotherapy: cryptic anticancer vaccines, Semin. Immunol, vol.22, pp.113-137, 2010. ,
Decoding cell death signals in inflammation and immunity, Cell, vol.140, pp.798-804, 2010. ,
Calreticulin exposure dictates the immunogenicity of cancer cell death, Nat. Med, vol.13, pp.54-61, 2007. ,
URL : https://hal.archives-ouvertes.fr/inserm-00451702
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death, EMBO J, vol.28, pp.578-90, 2009. ,
The cotranslocation of ERp57 and calreticulin determines the immunogenicity of cell death, Cell Death Differ, vol.15, pp.1499-509, 2008. ,
Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8, Cell Death Differ, vol.21, pp.59-68, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02109979
Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists, Cell Death Differ, vol.21, pp.69-78, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02047406
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation, Nature, vol.418, pp.191-196, 2002. ,
The redox protein HMGB1 regulates cell death and survival in cancer treatment, Autophagy, vol.6, pp.1181-1184, 2010. ,
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy, Nat. Med, vol.13, pp.1050-1059, 2007. ,
URL : https://hal.archives-ouvertes.fr/hal-00316924
Antitumor immunity induced after ? irradiation, Neoplasia, vol.16, pp.319-347, 2014. ,
, Chemotherapy induces ATP release from tumor cells. cc, vol.8, pp.3723-3731, 2009.
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance, Nature, vol.461, pp.282-288, 2009. ,
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors, Nat. Med, vol.15, pp.1170-1178, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00419823
Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity, Cancer Research, vol.70, pp.855-863, 2010. ,
Molecular mechanisms of ATP secretion during immunogenic cell death, Cell Death Differ, vol.21, pp.79-91, 2014. ,
Pannexin 1 channels mediate "find-me" signal release and membrane permeability during apoptosis, Nature, vol.467, pp.863-870, 2010. ,
Autophagydependent anticancer immune responses induced by chemotherapeutic agents in mice, Science, vol.334, pp.1573-1580, 2011. ,
Alpha Particles Induce Autophagy in Multiple Myeloma Cells, Front Med (Lausanne), vol.2, p.74, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01817484
Sensitization to radiation-induced DNA damage accelerates loss of bcl-2 and increases apoptosis and autophagy, Cancer Biol. Ther, vol.7, pp.1561-1567, 2008. ,
DNA damage and autophagy, Mutat. Res, vol.711, pp.158-66, 2011. ,
Radiation combined with hyperthermia induces HSP70-dependent maturation of dendritic cells and release of pro-inflammatory cytokines by dendritic cells and macrophages, Radiother Oncol, vol.101, pp.109-124, 2011. ,
Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines, Radiat Oncol, vol.9, p.89, 2014. ,
The role of heat shock protein 70 (Hsp70) in radiation-induced immunomodulation, Cancer Lett, vol.368, pp.179-84, 2015. ,
Combining radiotherapy and cancer immunotherapy: a paradigm shift, J. Natl. Cancer Inst, vol.105, pp.256-65, 2013. ,
Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity, J. Immunol, vol.180, pp.3132-3141, 2008. ,
Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation, Radiat. Res, vol.173, pp.418-443, 2010. ,
Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells, The Journal of Immunology, vol.181, pp.3099-107, 2008. ,
Induction of the expression of the interleukin-1 beta gene in mouse spleen by ionizing radiation, Radiat. Res, vol.133, pp.321-327, 1993. ,
The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity, Cancer Research, vol.71, pp.2488-96, 2011. ,
Radiation as an immune modulator, Semin Radiat Oncol, vol.23, pp.273-80, 2013. ,
Oxidative stress promotes ligand-independent and enhanced ligand-dependent tumor necrosis factor receptor signaling, J. Biol. Chem, vol.283, pp.23419-23447, 2008. ,
Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication, Cancer Research, vol.62, pp.1462-70, 2002. ,
Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor, J. Immunol, vol.174, pp.7516-7539, 2005. ,
The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant, Cancer Treat. Rev, vol.41, pp.503-513, 2015. ,
Local low-dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A pre-clinical study, Int. J. Cancer, vol.72, pp.1003-1010, 1997. ,
,
, Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2), Radiat Oncol Investig, vol.5, pp.54-61, 1997.
Otter Den W. Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2, Cancer Research, vol.49, pp.7037-7077, 1989. ,
Presence of cytotoxic B220+CD3+CD4-CD8-cells correlates with the therapeutic efficacy of lymphoma treatment with IL-2 and/or IL-12, J. Immunother, vol.27, pp.107-122, 2004. ,
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas, Leuk. Lymphoma, vol.51, pp.1241-50, 2010. ,
A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation, J. Immunother, vol.33, pp.326-359, 2010. ,
Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: a pilot study, Bone Marrow Transplant, vol.49, pp.73-82, 2014. ,
Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma, Blood, vol.102, pp.1449-57, 2003. ,
The use of agonistic anti-CD40 therapy in treatments for cancer, Int. Rev. Immunol, vol.31, pp.246-66, 2012. ,
Sensitization of multiple myeloma and B lymphoma lines to dexamethasone and gamma-radiation-induced apoptosis by CD40 activation, Apoptosis, vol.10, pp.123-157, 2005. ,
Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials, Immunopharmacol Immunotoxicol, vol.36, pp.96-104, 2014. ,
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors, J Hematol Oncol, vol.7, p.44, 2014. ,
Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma, Blood, vol.121, pp.251-260, 2013. ,
Modes of action of TLR7 agonists in cancer therapy, Immunotherapy, vol.6, pp.1085-95, 2014. ,
Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma, J Hematol Oncol, vol.8, p.21, 2015. ,
Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12, Clin Lymphoma Myeloma Leuk, vol.7, pp.524-558, 2007. ,
Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-?: implications for therapy of cutaneous T-cell lymphoma, Leuk. Lymphoma, vol.52, pp.1970-1979, 2011. ,
Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies, Am. J. Hematol, vol.87, pp.953-959, 2012. ,
Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer, Clin. Cancer Res, vol.18, pp.6668-78, 2012. ,
A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models, Int. J. Cancer, vol.135, pp.820-829, 2014. ,
Combining ?-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction, PLoS ONE, vol.10, p.130249, 2015. ,
Systematic review of case reports on the abscopal effect, Curr Probl Cancer, vol.40, pp.25-37, 2016. ,
Strategies for combining immunotherapy with radiation for anticancer therapy, Immunotherapy, vol.7, pp.967-80, 2015. ,
Current Clinical Trials Testing Combinations of Immunotherapy and Radiation, Semin Radiat Oncol, vol.25, pp.54-64, 2015. ,
Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes, Int. J. Radiat. Oncol. Biol. Phys, vol.88, pp.986-97, 2014. ,
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study, J. Clin. Oncol, vol.28, pp.4324-4356, 2010. ,
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma, Am. J. Hematol, vol.88, pp.589-93, 2013. ,
Rituximab: modes of action, remaining dispute and future perspective, Future Oncol, vol.10, pp.2481-92, 2014. ,
Monoclonal antibodies for cancer immunotherapy, Lancet, vol.373, pp.1033-1073, 2009. ,
Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger longterm protective T cell immunity in follicular lymphoma patients, Clin. Dev. Immunol, p.875343, 2013. ,
Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma, Clin. Cancer Res, vol.14, pp.7088-94, 2008. ,
Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Yibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma, Exp Hematol Oncol, vol.4, p.17, 2015. ,
A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402, Br. J. Haematol, vol.170, pp.679-86, 2015. ,
Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial, Lancet Oncol, vol.16, pp.795-803, 2015. ,
Biology and clinical application of CAR T cells for B cell malignancies, Int. J. Hematol, vol.104, pp.6-17, 2016. ,
Optimizing T-cell receptor gene therapy for hematologic malignancies, Blood, vol.127, pp.3305-3316, 2016. ,
Big opportunities for small molecules in immuno-oncology, Nat Rev Drug Discov, vol.14, pp.603-625, 2015. ,